Investigational drug · Phase 2
C-CAR168
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "C-CAR168"
First trial start
2026
Sep 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "C-CAR168", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lupus Nephritis (LN)
- Systemic Lupus Erythematosus (SLE)
- Autoimmune Diseases
- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis
- Secondary Progress Multiple Sclerosis (SPMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- MS
- MS (Multiple Sclerosis)
- Neuro-Degenerative Disease
Approved drugs for the same conditions: Multiple sclerosis · Lupus (SLE) · Neurology · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "C-CAR168" as an intervention, largest first.
AbelZeta Inc.Industry
NCT07825389 · 119 participants (planned) · Start Feb 2027 · Primary completion Feb 2030
Drug: C-CAR168 · For: Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progress Multiple Sclerosis (SPMS) and 6 more
Sites: Gilbert, Arizona; La Jolla, California
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard TherapyNot yet recruiting
AbelZeta Inc.Industry
NCT07729826 · 50 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 31, 2028
Drug: C-CAR168 · For: Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Autoimmune Diseases
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyRecruiting
RenJi HospitalAcademic, hospital or other
NCT06249438 · 30 participants (planned) · Start Mar 20, 2024 · Primary completion Mar 2027
Drug: CD20/BCMA-directed CAR-T cells · For: Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM); Neuromyelitis Optica Spectrum Disorders (NMOSD) and 3 more
Sites: Shanghai, China
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyNot yet recruiting
The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
NCT07676266 · 18 participants (planned) · Start Jul 2026 · Primary completion Nov 2027
Drug: CD20/BCMA-directed CAR-T cells Autologous 2nd generation · For: Multiple Sclerosis (MS); Myasthenia Gravis (MG); Neuromyelitis Optica Spectrum Disorder and 3 more
Sites: Qingdao, China
- A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard TherapyNot yet recruiting
Huashan HospitalAcademic, hospital or other
NCT07341828 · 15 participants (planned) · Start Feb 2026 · Primary completion Jun 2027
Drug: CD20/BCMA-directed CAR-T cells · For: Multiple Sclerosis (MS); Neuromyelitis Optica Spectrum Disorders (NMOSD); Autoimmune Encephalitis and 1 more
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard TherapyNot yet recruiting
AbelZeta Inc.Industry
NCT07854483 · 12 participants (planned) · Start Mar 2027 · Primary completion Dec 2028
Drug: C-CAR168 · For: Systemic Sclerosis (SSc); Systemic Sclerosis; Systemic Sclerosis (Scleroderma) and 3 more
Sites: Gilbert, Arizona
AbelZeta Inc.Industry
NCT06935474 · 0 participants · Start Jul 2026 · Primary completion May 2029
Drug: C-CAR168 · For: Lupus Nephritis (LN)
Sites: Rockville, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Case Report: CD20/BCMA bispecific CAR-T therapy for progressive multiple sclerosis.
Ling Z, Liu X, Li W, et al. · Front Immunol 2026
Also in development for Lupus Nephritis (LN)
- HSK39297 200mgQDPhase 23 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- BCMA-CD19-IL-15Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
- CRC01Phase 22 trials
Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
- HSK39297 300mgQDPhase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Lupus Nephritis (LN)
- ICG318Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
- ADX-097Phase 21 trial
Akebia Therapeutics · IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- HLX01Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
- HLX79Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.